• Privacy Policy
  • Terms and Conditions
  • Contact
Sunday, July 13, 2025
Pharma Info Nepal
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Updates

FDA Statement on Johnson & Johnson COVID-19 Vaccine

FDA Statement on Johnson & Johnson COVID-19 Vaccine

Pharma Info Nepal by Pharma Info Nepal
April 13, 2021
in Updates
0
FDA Statement on Johnson & Johnson COVID-19 Vaccine
252
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

FDA Statement on Johnson & Johnson COVID-19 Vaccine

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine, severe type of blood clot in individuals after receiving the J&J vaccine

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.

On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.

Common Side Effects

The most commonly reported side effects were pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects occurred within 1-2 days following vaccination and were mild to moderate in severity and lasted 1-2 days.


  • FDA Approved Drugs in 2020
  • Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

 

 

Tags: Medicine InformationPharmacy Updates
Previous Post

“Pharmacy: Always trusted for your health” is the theme of this year’s World Pharmacists Day

Next Post

Adverse Drug Reaction (ADR)

Pharma Info Nepal

Pharma Info Nepal

Pharma Info Nepal is the leading platform for pharmacy professionals, students, and healthcare workers in Nepal. We provide verified job updates, exam preparation resources (NPC & Loksewa), scholarships, and professional guidelines. Trusted by thousands, we also share timely updates from DDA, NPC, and MoHP to keep the pharmacy community informed and empowered. Join us to grow, learn, and lead in Nepal’s pharmacy sector. Thanks for visiting us | Pharma Info Nepal: Nepal’s No.1 Pharmacy Blog

Related Posts

M. Pharmacy Colleges in Nepal
Colleges

M. Pharmacy Colleges in Nepal

July 8, 2025
List of CTEVT Constituent Colleges in Nepal
D Pharmacy

List of CTEVT Constituent Colleges in Nepal

June 29, 2025
Dapagliflozin Mechanism Uses Side Effects Contraindications and Dosage
Pharmacy Notes

Dapagliflozin: Mechanism, Uses, Side Effects, Contraindications, and Dosage

June 20, 2025
Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)
Updates

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)

June 15, 2025
Best NPC License Preparation Classes in Nepal for Pharmacy Students
License

Best NPC License Preparation Classes in Nepal for Pharmacy Students

May 22, 2025
WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook
Updates

WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook

May 21, 2025
Load More
Next Post
Adverse Drug Reaction (ADR)

Adverse Drug Reaction (ADR)

Discussion about this post

Recommended

Nepal Pharmacy Council License Exam Model Question Set - 1

Nepal Pharmacy Council License Exam Model Question Set – 1

July 10, 2025
PHARMA JOB VACANCIES NEPAL

Vacancy Announcement Pharmacist and Pharmacy Assistant Nepal Army

July 10, 2025
M. Pharmacy Colleges in Nepal

M. Pharmacy Colleges in Nepal

July 8, 2025
Pharmacist Job Vacancy Nepal

Vacancy Announcement Magnus Pharma Pvt. Ltd QA, QC, and Production

July 1, 2025
List of CTEVT Constituent Colleges in Nepal

List of CTEVT Constituent Colleges in Nepal

June 29, 2025
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

About Pharma Info Nepal

Pharma Info Nepal is a dedicated platform led by Nabin Bista, focused on empowering pharmacy students and professionals in Nepal. We provide high-quality educational resources, exam preparation materials, and professional guidance for pharmacy licensure exams and beyond. Our mission is to uplift the pharmacy profession in Nepal by fostering knowledge, skills, and excellence in pharmaceutical practice.

Explore our services, stay updated on pharmacy trends, and join a community striving for innovation and professionalism in healthcare.

Important Information

All content available on this website, including text, images, files, and other resources, is strictly protected under applicable copyright and intellectual property laws. Any reuse, reproduction, or redistribution of materials without prior written permission from Pharma Info Nepal is prohibited and may result in legal action.

Pharma Info Nepal operates as a registered company dedicated to maintaining the authenticity and integrity of its content and services.

Thank you for respecting our policies and supporting our mission to advance pharmacy education and practice.

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Pharmacy Notes
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
  • Pharmacy Notes

© 2025 Pharma Info Nepal | All Rights Reserved

error:
No Result
View All Result
  • Courses
  • Questions
  • Downloads
  • About Pharma Info Nepal 

© 2025 Pharma Info Nepal | All Rights Reserved